U.S. SENATOR ROBERT BENNETT (R-UT) CHAIRMAN U.S. SENATOR ROBERT BENNETT (R-UT) HOLDS A HEARING ON FISCAL YEAR 2007 APPROPRIATIONS FOR THE FOOD AND DRUG ADMINISTRATION From: Washington Transcript Service | Date: March 14, 2006 | . Provided by ProQuest LLC.Copyright information

Washington Transcript Service

03-14-2006

U.S. SENATE COMMITTEE ON APPROPRIATIONS: SUBCOMMITTEE ON
AGRICULTURE, RURAL DEVELOPMENT AND RELATED AGENCIES HOLDS
A HEARING ON FISCAL YEAR 2007 APPROPRIATIONS FOR THE FOOD
AND DRUG ADMINISTRATION
MARCH 14, 2006
SPEAKERS:
U.S. SENATOR ROBERT BENNETT (R-UT)
CHAIRMAN
U.S. SENATOR THAD COCHRAN (R-MS)
...

Related newspaper, magazine, and journal articles from HighBeam Research

	Bush FDA nominee under fire Deseret News (Salt Lake City) ; WASHINGTON -- Dr. Andrew von Eschenbach, nominated to head the Food and Drug Administration, insisted at his confirmation hearing Tuesday that "medical ideology" -- not politics -- guided his handling of proposed over-the-counter sales of the morning-after contraceptive. Senators hammered von
	Dr von Eschenbach's vision: FDA's newest commissioner faces multiple challenges Formulary ; Andrew von Eschenbach, MD, has faced a number of tough issues since he was sworn in as FDA's commissioner in December 2006, not the least of which is drug safety. Fewer new drugs have been coming to market, and pressure continues to mount for FDA to do more with limited resources. Legislation to
	FDA signals Plan B move: Agency says it might allow the sale of morning-after pill over the counter. Baltimore Sun (Baltimore, MD) ; ... over the counter sales were raised to 18 years. Copyright (c) 2006, The Baltimore Sun Distributed by McClatchy-Tribune Business News. For reprints, email tmsreprints@permissionsgroup.com, call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write ...
	Acting no longer, von Eschenbach tackles backlog.(NEWS)(Andrew Von Eschenbach) Medical Marketing & Media ; ANDREW VON Eschenbach and the FDA are keeping quiet about the commissioner's formal priorities until he is sworn in this month, but his agenda is likely to correspond closely with that articulated in the Institute of Medicine (IOM) report of 2006. The report was commissioned by FDA to take a hard
	Supplements' fate under new FDA chief uncertain Natural Foods Merchandiser ; Dr. Andrew von Eschenbach, who was appointed acting commissioner of the U.S. Food and Drug Administration Sept. 23 after Commissioner Lester Crawford abruptly resigned, may never take over the job permanently. "That sounds correct to me," said an FDA spokesperson, addressing rumors that von
	Bush picks acting FDA head to take over as agency chief: Democrats oppose von Eschenbach over contraceptive's lack of availability. Baltimore Sun (Baltimore, MD) ; ... deaths - and national scandals, she said. Copyright (c) 2006, The Baltimore Sun Distributed by Knight Ridder/Tribune Business News. For information on republishing this content, contact us at (800) 661-2511 (U.S.), (213) 237-4914 (worldwide), fax (213) 237-65 ...
	New chief of FDA garners mixed reviews.(BUSINESS) The Washington Times ; Byline: Marguerite Higgins, THE WASHINGTON TIMES The Food and Drug Administration's new acting commissioner is getting compliments for his government experience but criticism for his history of seeking quick drug approvals. President Bush on Friday named Dr. Andrew C. von Eschenbach to replace
	Senate grills FDA nominee on morning-after pill: Committee takes issue with timing of Plan B report Chicago Sun-Times ; WASHINGTON -- Dr. Andrew von Eschenbach, nominated to head the Food and Drug Administration, insisted at his confirmation hearing Tuesday that "medical ideology" -- not politics -- guided his handling of proposed over-the-counter sales of the morning-after contraceptive. Senators hammered von
	Hopes are high as von Eschenbach takes reins at FDA.(Andrew von Eschenbach)(Brief article) Chain Drug Review ; WASHINGTON -- Last month's Senate confirmation of Dr. Andrew von Eschenbach as commissioner of the Food and Drug Administration has won applause from a number of health care trade organizations, including the National Association of Chain Drug Stores. He is an effective and committed leader, and we
	Senate Approves FDA Chief; Frist Ends 'Holds' That Long Stalled Vote on Von Eschenbach The Washington Post ; The Senate broke with tradition yesterday in clearing a path for Andrew C. von Eschenbach to become commissioner of the Food and Drug Administration despite attempts by two lawmakers to block the final vote. In one of his last official acts, retiring Majority Leader Bill Frist (R-Tenn.) forced a

See all results.